Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 - Wikidata - wikimedia - TriplyDB

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

http://www.wikidata.org/entity/Q35266125

about

Trial Watch: Proteasomal inhibitors for anticancer therapy Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma Advances in understanding prognosis in myeloma.Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing.Towards the integration, annotation and association of historical microarray experiments with RNA-seq Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat.The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?Why proteasome inhibitors cannot ERADicate multiple myeloma.Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma.The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.Latest advances and current challenges in the treatment of multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.Perspectives in the treatment of multiple myeloma.Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.Metronomic chemotherapy.Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.Molecular mechanisms of acquired proteasome inhibitor resistance.Gene signature combinations improve prognostic stratification of multiple myeloma patients.Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a.

P2860

Q28082910-5E52D26C-59C1-4022-9A94-8FCAACDC046D Q28534703-8EC7D9E4-4B6A-47FE-8815-032611EBA3DD Q28537857-4992ECB1-97E9-444F-BBE3-1CABD47144CF Q28544663-D8B64282-6FE0-43F5-A2DB-2C7706A7A615 Q30244061-D369BDA4-E351-47F1-91C4-2399F0377067 Q33408052-EAD2C596-DF59-4D2B-9836-FFDD00C4B443 Q33774333-9ED3C6A3-20BE-47BC-96BF-5905CF31DE85 Q34316959-B4C6A05F-E1D7-4EA7-9C67-267CDC2B7FF4 Q34606998-715229DC-5084-48E8-8F82-374136188E03 Q35051525-8F5D0EB4-4649-4252-B6EF-95257AC2F50A Q35157421-38EBD293-C731-4164-B028-4629B7AEC5DF Q35607341-3A47FF50-BDAC-443B-AFAC-AACEDF1D79C1 Q35932154-63C337F5-C63E-4577-A3F5-BADCBA67BF1B Q36185955-74E06963-91E2-489E-8FBE-05A87D7B6C2A Q36193181-B0B1E45D-5699-4BA9-9EDE-CE65D0CE187B Q36208283-899FA4D9-3CE0-456D-9E51-4278BBBAA3AB Q36473629-4E03BCF5-13CA-4E65-A6E6-3E7519B5BACB Q36782511-2BC2617F-529A-46BC-A9A8-9C0BE5E0B741 Q37037265-11BCAFF0-D6DA-454F-8B35-B2412FDAE98E Q37096649-829DCF3C-8167-4CA5-AE95-9EB5418C986E Q37393383-A331C85A-029F-4B81-BEF1-87681EC30A30 Q37552056-AF749C11-E1D8-4258-A224-E5A0FA09357A Q37738092-BC2187F6-03C4-42B2-9534-4DA635B902EE Q37946246-95E7BE4A-9C91-43C5-9670-190ECE28A561 Q37986287-E18B7A5E-AF3A-4735-A8EF-C9C26FD126E5 Q38037600-8712A354-9D02-4AAE-9A85-1DEF681358CE Q38101343-70220551-767A-4FB5-850D-4B8FE551F8F9 Q38108391-93362FC6-7528-4942-B66C-215DAA9BFCC6 Q38165722-48697D0C-C4F1-4744-953F-83EC3E0F270F Q38192044-34F973CC-0F54-4616-BD21-5331CBBF0798 Q38202977-4ACA7D12-9F3C-487C-B75F-083EE4B441DA Q38248269-F14B33C2-CE50-4613-9CDB-44E11A8B78E3 Q38258197-726A37A0-3B7A-4282-BA31-825FA2965FFB Q38711624-3D161AB4-98E3-4DBD-81C3-5B3C7F621030 Q38776967-0340095D-D6A1-4486-ADA8-53E9AB6450F2 Q39174431-2EF39F96-4963-4AF9-9732-EFF59AC9399A Q39278628-DFA01CEC-5CEC-48FA-B44C-3A3ACCA785F1 Q40209753-1DFB280F-DA7E-4AA8-9B25-8D172F0FC549 Q40384505-C0E9B420-CF8C-4923-803B-0A42AFA2786A Q40516887-DC21F069-0B7C-4278-A44C-A64D7C165DA9

P2860

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

http://www.wikidata.org/entity/Q35266125

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacogenomics of bortezomib ...... a treated with Total Therapy 3

@ast

Pharmacogenomics of bortezomib ...... a treated with Total Therapy 3

@en

type

label

Pharmacogenomics of bortezomib ...... a treated with Total Therapy 3

@ast

Pharmacogenomics of bortezomib ...... a treated with Total Therapy 3

@en

prefLabel

Pharmacogenomics of bortezomib ...... a treated with Total Therapy 3

@ast

Pharmacogenomics of bortezomib ...... a treated with Total Therapy 3

@en

P1433

Q35266125-C7491C79-F8DD-462B-B19F-8546DDA1314C

P1476

Q35266125-F3D6EA86-00AB-43AE-A305-DFD33DC58E73

P2093

Q35266125-07B17FD2-A44A-4A64-9D08-0AC328162D46

Q35266125-2573E0EC-430F-43F5-977C-8AF1C0290BEF

Q35266125-2CBA845D-2A34-483D-9A95-2F52F07B4909

Q35266125-37364D67-FE1B-48DC-B112-B5115166D7C1

Q35266125-5ADC3C3E-A15B-42E7-B4F0-E14FBC82868D

Q35266125-69C376C0-BA10-43A9-81E3-A7F9F5FF9CE9

Q35266125-741D150C-1237-419B-B014-6A33CCD2B80E

Q35266125-7F4DA9FC-0425-43D4-84EE-F0D966D32CD3

Q35266125-9BC2310B-AA37-4D9E-89F3-BA046448D2C7

Q35266125-B59E8C23-EAFF-4FA9-AFB4-607DAB6EE0E1

P2860

Q35266125-0B64ADFF-F20D-4F56-917A-84C3610A9853

Q35266125-0EF5722E-6133-4F11-954F-175A3121ECD5

Q35266125-1D67332B-E43F-45B8-88FC-9F1B29BA37CC

Q35266125-1E4BE200-D5D1-41DD-BA28-A12B85683F65

Q35266125-26862368-E972-4E1D-BC59-33623364D064

Q35266125-35B7A0AF-B639-483E-B778-6E3DD592F992

Q35266125-3C7420EC-F1C0-492A-8B09-A36F86982AA4

Q35266125-40D7B383-5FE5-4B1C-BF72-CBE09D4FA9B1

Q35266125-4C4921FE-B033-451B-81D1-7057FFD2D544

Q35266125-57A54FDB-3EDA-462B-86D9-C29542BB1579

P304

Q35266125-3251F43C-CD97-45B3-AA0B-01B55741E8BA

P31

Q35266125-D3FDA9F2-5A74-4C7C-B086-11733204BFFB

P356

Q35266125-85733DB8-1F74-4502-BB00-6F45C31E48FC

P407

Q35266125-C0008991-4353-4FAD-BDD3-619F82AD4928

P433

Q35266125-63263B05-4160-4C27-856F-77005D6B90AF

P478

Q35266125-CDEA1B67-5D3D-49A6-AE4A-634A5EB84E89

P50

Q35266125-683E3D6F-B06B-485B-88C7-CB2975084FAE

Q35266125-81186891-F984-4FC3-B8A3-A7460A6C0120

Q35266125-BB640D1D-9520-4E48-9C40-E4B85A8A11FD

Q35266125-E7F63D7C-DD36-489B-9D65-517D1A1103FA

P577

Q35266125-95306805-2CC7-4AF7-9DA1-4ACAAF3378C1

P5875

Q35266125-A1DB2600-585F-4B39-A824-4204179B9CCD

P698

Q35266125-DF4532CD-2D2F-405F-9264-D64E12D05411

P921

Q35266125-816F752A-9C84-46D4-9C9C-78135876E56A

P932

Q35266125-29B84794-825E-49E9-8C2D-9B4DFC762182

P356

BLOOD-2010-12-328252

P1433

P1476

Pharmacogenomics of bortezomib ...... a treated with Total Therapy 3

@en

P2093

Bijay Nair

http://www.w3.org/2001/XMLSchema#string

Christoph J Heuck

http://www.w3.org/2001/XMLSchema#string

Erming Tian

http://www.w3.org/2001/XMLSchema#string

Ichiro Hanamura

http://www.w3.org/2001/XMLSchema#string

John Crowley

http://www.w3.org/2001/XMLSchema#string

John D Shaughnessy

http://www.w3.org/2001/XMLSchema#string

Joshua Epstein

http://www.w3.org/2001/XMLSchema#string

Owen Stephens

http://www.w3.org/2001/XMLSchema#string

Pingping Qu

http://www.w3.org/2001/XMLSchema#string

Qing Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Evaluation of survival data and two new rank order statistics arising in its consideration.

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.

The molecular classification of multiple myeloma

International uniform response criteria for multiple myeloma.

P304

3512-3524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-12-328252

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51180241

http://www.w3.org/2001/XMLSchema#string

P698

21628408

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

3186329

http://www.w3.org/2001/XMLSchema#string